Guardant Health (FRA:5GH) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


FRA:5GH Guardant Health Inc FRA:5GH
67 GF Score
Price €122.16
GF Value €51.63
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Guardant Health Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Guardant Health's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:5GH vs LH, DGX, MEDP: Margin of Safety % (DCF Earnings Based) Comparison

For the Diagnostics & Research subindustry, Guardant Health's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Guardant Health Margin of Safety % (DCF Earnings Based) vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Guardant Health's Margin of Safety % (DCF Earnings Based) falls into.


FRA:5GH
67GF Score
Guardant Health Inc FRA:5GH
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Guardant Health (FRA:5GH) Overvalued in 2026?

Based on GuruFocus' analysis, Guardant Health stock appears to be overvalued. The current stock price of €122.16 is trading 136.6% above its estimated GF Value™ of €51.63. GuruFocus considers Guardant Health to be Significantly Overvalued.

Key valuation signals for FRA:5GH:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €51.63 vs. price of €122.16 (136.6% above fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the FRA:5GH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Guardant Health Business Description

Other Exchanges GH:USA1GH:Italy5GH:Germany
Address 3100 Hanover Street, Palo Alto, CA, USA, 94304
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
67GF Score

Get the complete analysis for FRA:5GH

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€122.16
Price
€51.63
GF Value